{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T23:27:20Z","timestamp":1780702040066,"version":"3.54.1"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,9,3]],"date-time":"2014-09-03T00:00:00Z","timestamp":1409702400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s11926-014-0445-4","type":"journal-article","created":{"date-parts":[[2014,9,2]],"date-time":"2014-09-02T05:22:31Z","timestamp":1409635351000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Pneumocystis jirovecii Pneumonia in Patients Receiving Tumor-Necrosis-Factor-Inhibitor Therapy: Implications for Chemoprophylaxis"],"prefix":"10.1007","volume":"16","author":[{"given":"James A.","family":"Grubbs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Baddley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,3]]},"reference":[{"key":"445_CR1","first-page":"120","volume":"158","author":"J Vanek","year":"1952","unstructured":"Vanek J, Jirovec O. Parasitic pneumonia. Interstitial plasma cell pneumonia of premature, caused by pneumocystis Carinii. Zentralbl Bakteriol Parasitenkd Infektionskr Hyg. 1952;158:120\u20137.","journal-title":"Zentralbl Bakteriol Parasitenkd Infektionskr Hyg"},{"key":"445_CR2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1542\/peds.19.4.543","volume":"19","author":"DC Gajdusek","year":"1957","unstructured":"Gajdusek DC. Pneumocystis carinii: etiologic agent of interstitial plasma cell pneumonia of premature and young infants. Pediatrics. 1957;19:543\u201365.","journal-title":"Pediatrics"},{"key":"445_CR3","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/cncr.2820360912","volume":"36","author":"WT Hughes","year":"1975","unstructured":"Hughes WT, Feldman S, Aur RJ, Verzosa MS, Hustu HO, Simone JV. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer. 1975;36:2004\u20139.","journal-title":"Cancer"},{"key":"445_CR4","first-page":"65","volume":"43","author":"PD Walzer","year":"1976","unstructured":"Walzer PD, Schultz M, Western KA, Robbins JF. Pneumocystis carinii pneumonia and primary immune deficiency diseases. Natl Cancer Inst Monogr. 1976;43:65\u201374.","journal-title":"Natl Cancer Inst Monogr"},{"issue":"24","key":"445_CR5","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJM198112103052402","volume":"305","author":"H Masur","year":"1981","unstructured":"Masur H et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med. 1981;305(24):1431\u20138.","journal-title":"N Engl J Med"},{"key":"445_CR6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/thx.46.3.205","volume":"46","author":"A Wollner","year":"1991","unstructured":"Wollner A et al. Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for rheumatoid arthritis. Thorax. 1991;46:205\u20137.","journal-title":"Thorax"},{"issue":"4","key":"445_CR7","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M","volume":"42","author":"MM Ward","year":"1999","unstructured":"Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 1999;42(4):780\u20139.","journal-title":"Arthritis Rheum"},{"issue":"3 Pt 1","key":"445_CR8","first-page":"795","volume":"151","author":"FP Ognibene","year":"1995","unstructured":"Ognibene FP et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener\u2019s granulomatosis. Am J Respir Crit Care Med. 1995;151(3 Pt 1):795\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"445_CR9","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1136\/ard.2010.146365","volume":"70","author":"JR Curtis","year":"2011","unstructured":"Curtis JR et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis. 2011;70:1401\u20136. A study examining the risk for OI among patients starting on different TNFi revealing that risk for OI seems to be more based on factors apart from the TNFi used.","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"445_CR10","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in the randomized controlled trials. JAMA. 2006;295(19):2275\u201385.","journal-title":"JAMA"},{"issue":"9","key":"445_CR11","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3201\/eid0809.020096","volume":"8","author":"JR Stringer","year":"2002","unstructured":"Stringer JR et al. A new name for Pneumocystis from humans and new perspectives on the host-pathogen relationship. Emerg Infect Dis. 2002;8(9):891\u20136.","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"445_CR12","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1086\/319340","volume":"32","author":"SL Vargas","year":"2001","unstructured":"Vargas SL et al. Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clin Infect Dis. 2001;32(6):855\u201361.","journal-title":"Clin Infect Dis"},{"key":"445_CR13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1469-0691.2004.00974.x","volume":"10","author":"N Respaldiza","year":"2004","unstructured":"Respaldiza N et al. High seroprevalence of Pneumocystis infection in Spanish children. Clin Microbiol Infect. 2004;10:1029\u201331.","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"445_CR14","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/cid\/cit413","volume":"57","author":"BJ Nankivell","year":"2013","unstructured":"Nankivell BJ et al. Molecular epidemiology linking multihospital clusters of opportunistic Pneumocystis jirovecii pneumonia. Clin Infect Dis. 2013;57(7):1058\u20139.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"445_CR15","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3201\/eid1805.111432","volume":"18","author":"C Damiani","year":"2012","unstructured":"Damiani C et al. Possible nosocomial transmission of Pneumocystis jirovecii. Emerg Infect Dis. 2012;18(5):877\u20138.","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"445_CR16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3201\/eid0603.000306","volume":"6","author":"CB Beard","year":"2000","unstructured":"Beard CB et al. Genetic variation in Pneumocystis carinii isolates from different geographic regions: implications for transmission. Emerg Infect Dis. 2000;6(3):265\u201372.","journal-title":"Emerg Infect Dis"},{"key":"445_CR17","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s100960000354","volume":"19","author":"A Dumoulin","year":"2000","unstructured":"Dumoulin A et al. Transmission of Pneumocystis carinii disease from immunocompetent contacts of infected hosts to susceptible hosts. Eur J Clin Microbiol Infect Dis. 2000;19:671\u20138.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"11","key":"445_CR18","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1128\/JCM.39.11.3877-3882.2001","volume":"39","author":"RF Miller","year":"2001","unstructured":"Miller RF, Ambrose HE, Wakefield AE. Pneumocystis carinii f. sp. hominis DNA in immunocompetent healthcare workers in contact with patients with P. carinii pneumonia. J Clin Microbiol. 2001;39(11):3877\u201382.","journal-title":"J Clin Microbiol"},{"key":"445_CR19","doi-asserted-by":"crossref","unstructured":"Fong S, et al. Antibody responses against Pneumocystis jirovecii in health care workers over time. Emerg Infect Dis. Oct 2013;19(10). [Internet].","DOI":"10.3201\/eid1910.121836"},{"issue":"1","key":"445_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-3062.2009.00447.x","volume":"12","author":"S Gianella","year":"2010","unstructured":"Gianella S et al. Molecular evidence of interhuman transmission in an outbreak of Pneumocystis jirovecii pneumonia among renal transplant recipients. Transpl Infect Dis. 2010;12(1):1\u201310.","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"445_CR21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2362.2010.02415.x","volume":"41","author":"G Wissman","year":"2011","unstructured":"Wissman G et al. Pneumocystis jirovecii colonization in patients treated with infliximab. Eur J Clin Investig. 2011;41(3):343\u20138. A study describing the incidence of respiratory specimen PCR positivity for P. jirovecii DNA in patients on infliximab.","journal-title":"Eur J Clin Investig"},{"key":"445_CR22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/03009742.2011.630328","volume":"41","author":"C Fritzsche","year":"2012","unstructured":"Fritzsche C et al. High prevalence of Pneumocystis jirovecii colonization among patients with autoimmune inflammatory diseases and corticosteroid therapy. Scand J Rheumatol. 2012;41:208\u201313.","journal-title":"Scand J Rheumatol"},{"key":"445_CR23","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3899\/jrheum.081270","volume":"36","author":"S Mori","year":"2009","unstructured":"Mori S, Cho I, Sugimoto M. A follow up study of asymptomatic carriers of Pneumocystis jirovecii during immunosuppressive therapy for rheumatoid arthritis. J Rheumatol. 2009;36:1600\u20135.","journal-title":"J Rheumatol"},{"key":"445_CR24","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/0003-4819-100-5-663","volume":"100","author":"JA Kovacs","year":"1984","unstructured":"Kovacs JA et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984;100:663\u201371.","journal-title":"Ann Intern Med"},{"key":"445_CR25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2169\/internalmedicine.47.0702","volume":"47","author":"H Tokuda","year":"2008","unstructured":"Tokuda H et al. Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in Acquired Immunodeficiency Syndrome: a multicenter study. Intern Med. 2008;47:915\u201323.","journal-title":"Intern Med"},{"issue":"3","key":"445_CR26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1378\/chest.91.3.323","volume":"91","author":"LJ DeLorenzo","year":"1987","unstructured":"DeLorenzo LJ, Huang CT, Maguire GP, Stone DJ. Roentgenographic patterns of Pneumocystis carinii pneumonia in 104 patients with AIDS. Chest. 1987;91(3):323\u20137.","journal-title":"Chest"},{"issue":"7","key":"445_CR27","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/archinte.1992.00400190032008","volume":"152","author":"CA Kennedy","year":"1992","unstructured":"Kennedy CA, Goetz MB. Atypical roentgenographic manifestations of Pneumocystis carinii pneumonia. Arch Intern Med. 1992;152(7):1390\u20138.","journal-title":"Arch Intern Med"},{"issue":"6","key":"445_CR28","doi-asserted-by":"crossref","first-page":"W555","DOI":"10.2214\/AJR.11.7329","volume":"198","author":"JP Kanne","year":"2012","unstructured":"Kanne JP, Yandow DR, Meyer CA. Pneumocystis jiroveci pneumonia: high-resolution CT findings in patients with and without HIV infection. AJR Am J Roentgenol. 2012;198(6):W555\u201361.","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"445_CR29","first-page":"226","volume":"133","author":"AE Pitchenik","year":"1986","unstructured":"Pitchenik AE et al. Sputum examination for the diagnosis of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Am Rev Respir Dis. 1986;133(2):226\u20139.","journal-title":"Am Rev Respir Dis"},{"issue":"4","key":"445_CR30","first-page":"515","volume":"133","author":"TD Bigby","year":"1986","unstructured":"Bigby TD et al. The usefulness of induced sputum in the diagnosis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. Am Rev Respir Dis. 1986;133(4):515.","journal-title":"Am Rev Respir Dis"},{"issue":"4","key":"445_CR31","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1183\/09031936.02.01372002","volume":"20","author":"M Cruciani","year":"2002","unstructured":"Cruciani M et al. Meta-analysis of diagnostic procedures for Pneumocystis carinii pneumonia in HIV-1-infected patients. Eur Respir J. 2002;20(4):982\u20139.","journal-title":"Eur Respir J"},{"issue":"2","key":"445_CR32","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1183\/09031936.03.00035303","volume":"21","author":"D Turner","year":"2003","unstructured":"Turner D, Schwarz Y, Yust I. Induced sputum for diagnosing Pneumocystis carinii pneumonia in HIV patients: new data, new issues. Eur Respir J. 2003;21(2):204\u20138.","journal-title":"Eur Respir J"},{"issue":"5","key":"445_CR33","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1164\/ajrccm\/140.5.1204","volume":"140","author":"AH Limper","year":"1989","unstructured":"Limper AH, Offord KP, Smith TF, Martin 2nd WJ. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis. 1989;140(5):1204\u20139.","journal-title":"Am Rev Respir Dis"},{"issue":"Pt 7","key":"445_CR34","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1099\/jmm.0.45528-0","volume":"53","author":"P Flori","year":"2004","unstructured":"Flori P et al. Comparison between real-time PCR, conventional PCR and different staining techniques for diagnosing Pneumocystis jiroveci pneumonia from bronchoalveolar lavage specimens. J Med Microbiol. 2004;53(Pt 7):603\u20137.","journal-title":"J Med Microbiol"},{"issue":"2","key":"445_CR35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1128\/JCM.06036-11","volume":"50","author":"F Botterel","year":"2012","unstructured":"Botterel F et al. Clinical significance of quantifying Pneumocystis jirovecii DNA by using real-time PCR in bronchoalveolar lavage fluid from immunocompromised patients. J Clin Microbiol. 2012;50(2):227\u201331. The only blinded study published thus far on the natural history on symptomatic patients with P. jirovecii DNA positivity from BAL.","journal-title":"J Clin Microbiol"},{"key":"445_CR36","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/00365540601150497","volume":"39","author":"UM Overgaard","year":"2007","unstructured":"Overgaard UM, Helweg-Larsen J. Pneumocystis jirovecii pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002\u20132004. Scand J Infect Dis. 2007;39:589\u201395.","journal-title":"Scand J Infect Dis"},{"issue":"4","key":"445_CR37","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1164\/rccm.200401-094OC","volume":"170","author":"A Morris","year":"2004","unstructured":"Morris A et al. Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am J Respir Crit Care Med. 2004;170(4):408\u201313.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"445_CR38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1469-0691.2005.01337.x","volume":"12","author":"S Vidal","year":"2006","unstructured":"Vidal S et al. Pneumocystis jirovecii colonization in patients with interstitial lung disease. Clin Microbiol Infect. 2006;12(3):231\u20135.","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"445_CR39","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1128\/JCM.01554-13","volume":"51","author":"C Damiani","year":"2013","unstructured":"Damiani C et al. Combined quantification of pulmonary Pneumocystis jirovecii DNA and serum (1\u20133)-beta-D-glucan for differential diagnosis of Pneumocystis pneumonia and Pneumocystis colonization. J Clin Microbiol. 2013;51(10):3380\u20138.","journal-title":"J Clin Microbiol"},{"key":"445_CR40","unstructured":"Evaluation and Safety Center for Devices and Radiological Health, FDA. 21. May 2004, posting date. Glucatell (1-2-beta-d-glucan serological assay). [Online.] http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfrl\/ldetails.cfm?lid=346 . Accessed 19 June 2014."},{"issue":"7","key":"445_CR41","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1086\/605579","volume":"49","author":"T Watanabe","year":"2009","unstructured":"Watanabe T et al. Serum (1\u20133) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis. 2009;49(7):1128\u201331.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"445_CR42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/cid\/cir335","volume":"53","author":"PE Sax","year":"2011","unstructured":"Sax PE et al. Blood (1\u20133) beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia. Clin Infect Dis. 2011;53(2):197\u2013202.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"445_CR43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1128\/JCM.05267-11","volume":"50","author":"A Onishi","year":"2012","unstructured":"Onishi A et al. Diagnostic accuracy of serum 1,3-beta-D-glucan for Pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol. 2012;50(1):7\u201315.","journal-title":"J Clin Microbiol"},{"issue":"10","key":"445_CR44","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1128\/AAC.00658-06","volume":"50","author":"FM Marty","year":"2006","unstructured":"Marty FM et al. Reactivity of (1\u20133)-beta-D-glucan assay with commonly used intravenous antimicrobials. Antimicrob Agents Chemother. 2006;50(10):3450\u20133.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"445_CR45","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1086\/588563","volume":"46","author":"M Mennink-Kersten","year":"2008","unstructured":"Mennink-Kersten M et al. Pseudomonas aeruginosa as a cause of 1, 3-beta-D-glucan assay reactivity. Clin Infect Dis. 2008;46(12):1930\u20131.","journal-title":"Clin Infect Dis"},{"key":"445_CR46","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1523-1755.2001.00802.x","volume":"60","author":"H Kanda","year":"2001","unstructured":"Kanda H et al. Influence of various hemodialysis membranes on the plasma 1, 3-beta-D-glucan level. Kidney Int. 2001;60:319\u201323.","journal-title":"Kidney Int"},{"issue":"9","key":"445_CR47","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1046\/j.1537-2995.2002.00162.x","volume":"42","author":"M Usami","year":"2002","unstructured":"Usami M et al. Positive 1, 3-beta-D-glucan in blood components and release of 1, 3-beta-D-glucan from depth-type membrane filters for blood processing. Transfusion. 2002;42(9):1189\u201395.","journal-title":"Transfusion"},{"key":"445_CR48","unstructured":"Centers for Disease Control and Prevention. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR 2009;58"},{"key":"445_CR49","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/ajt.12119","volume":"13","author":"SI Martin","year":"2013","unstructured":"Martin SI, Fishman JA, and the AST Infectious Diseases Community of Practice. Pneumocystis Pneumonia in Solid Organ Transplantation. Am J Transplant. 2013;13:272\u20139.","journal-title":"Am J Transplant"},{"key":"445_CR50","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-105-1-37","volume":"105","author":"JM Wharton","year":"1986","unstructured":"Wharton JM, Coleman DL, Wofsy CB, et al. Trimethoprim\u2013sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med. 1986;105:37\u201344.","journal-title":"Ann Intern Med"},{"key":"445_CR51","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00002030-199203000-00007","volume":"6","author":"NC Klein","year":"1992","unstructured":"Klein NC, Duncanson FP, Lenox TH, et al. Trimethoprim\u2013sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial. AIDS. 1992;6:301\u20135.","journal-title":"AIDS"},{"key":"445_CR52","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-109-4-280","volume":"109","author":"FR Sattler","year":"1988","unstructured":"Sattler FR, Cowan R, Nielsen DM, et al. Trimethoprim\u2013sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a prospective, noncrossover study. Ann Intern Med. 1988;109:280\u20137.","journal-title":"Ann Intern Med"},{"issue":"6","key":"445_CR53","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/jac\/dkp372","volume":"64","author":"J Helweg-Larsen","year":"2009","unstructured":"Helweg-Larsen J, Benfield T, Atzori C, Miller RF. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. J Antimicrob Chemother. 2009;64(6):1282\u201390.","journal-title":"J Antimicrob Chemother"},{"key":"445_CR54","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/01.aids.0000168974.67090.70","volume":"19","author":"K Crothers","year":"2005","unstructured":"Crothers K, Beard CB, Turner J, et al. Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations. AIDS. 2005;19:801\u20135.","journal-title":"AIDS"},{"key":"445_CR55","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.3201\/eid1010.030994","volume":"10","author":"L Huang","year":"2004","unstructured":"Huang L, Crothers K, Atzori C, et al. Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance. Emerg Infect Dis. 2004;10:1721\u20138.","journal-title":"Emerg Infect Dis"},{"key":"445_CR56","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/archinte.161.12.1529","volume":"161","author":"RA Smego Jr","year":"2001","unstructured":"Smego Jr RA, Nagar S, Maloba B, et al. A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. Arch Intern Med. 2001;161:1529\u201333.","journal-title":"Arch Intern Med"},{"key":"445_CR57","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/QAI.0b013e31816de84d","volume":"48","author":"T Benfield","year":"2008","unstructured":"Benfield T, Atzori C, Miller RF, et al. Second-line salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia: a case series and systematic review. J Acquir Immune Defic Syndr. 2008;48:63\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"445_CR58","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00002030-200101260-00010","volume":"15","author":"DM Rosenberg","year":"2001","unstructured":"Rosenberg DM, McCarthy W, Slavinsky J, et al. Atovaquone suspension for treatment of Pneumocystis carinii pneumonia in HIV-infected patients. AIDS. 2001;15:211\u201321.","journal-title":"AIDS"},{"key":"445_CR59","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7326\/0003-4819-121-3-199408010-00003","volume":"121","author":"MN Dohn","year":"1994","unstructured":"Dohn MN, Weinberg WG, Torres RA, et al. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group. Ann Intern Med. 1994;121:174\u201380.","journal-title":"Ann Intern Med"},{"key":"445_CR60","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1001\/jama.259.8.1185","volume":"259","author":"MA Fischl","year":"1988","unstructured":"Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA. 1988;259:1185\u20139.","journal-title":"JAMA"},{"issue":"2","key":"445_CR61","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/00042560-199706010-00002","volume":"15","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Griffith L, Guyatt GH, Opravil M. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15(2):104\u201314.","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"issue":"9","key":"445_CR62","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4065\/82.9.1052","volume":"82","author":"H Green","year":"2007","unstructured":"Green H et al. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV patients: systemic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82(9):1052\u20139.","journal-title":"Mayo Clin Proc"},{"key":"445_CR63","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1046\/j.1365-2125.1997.00590.x","volume":"43","author":"MW Myers","year":"1997","unstructured":"Myers MW, Jick H. Hospitalization for serious blood and skin disorders following co-trimoxazole. Br J Clin Pharmacol. 1997;43:649\u201351.","journal-title":"Br J Clin Pharmacol"},{"key":"445_CR64","doi-asserted-by":"crossref","unstructured":"Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia in non-HIV immunocompromised patients. Cochrane Database Syst. Rev. 2007;(3):Art. No: CD005590.","DOI":"10.1002\/14651858.CD005590.pub2"},{"key":"445_CR65","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJM200104053441415","volume":"344","author":"A Warris","year":"2001","unstructured":"Warris A, Bjorneklett A. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med. 2001;344:1099\u2013100.","journal-title":"N Engl J Med"},{"key":"445_CR66","unstructured":"Keenan GF, Schaible TF, Boscia JA. Response to: Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med. 2001."},{"issue":"8","key":"445_CR67","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/rheumatology\/41.8.951","volume":"41","author":"TL Tai","year":"2002","unstructured":"Tai TL et al. Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology. 2002;41(8):951\u20132.","journal-title":"Rheumatology"},{"key":"445_CR68","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s10620-006-9250-x","volume":"52","author":"N Kaur","year":"2007","unstructured":"Kaur N, Mahl T. Pneumocystis jirovecii (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci. 2007;52:1481\u20134.","journal-title":"Dig Dis Sci"},{"key":"445_CR69","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","volume":"107","author":"GR Lichtenstein","year":"2012","unstructured":"Lichtenstein GR et al. Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107:1409\u201322.","journal-title":"Am J Gastroenterol"},{"key":"445_CR70","unstructured":"Baddley JW, et al. Non-viral opportunistic infections in new users of tumor necrosis factor inhibitor therapy: results of the Safety assessment of biological therapy (SABER) study. Ann Rheum Dis. 2013;1\u20137. A large retrospective study based on insurance claims data describing the incidence of OI in United States patients on TNFi."},{"issue":"8","key":"445_CR71","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","volume":"54","author":"WG Dixon","year":"2006","unstructured":"Dixon WG et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54(8):2368\u201376.","journal-title":"Arthritis Rheum"},{"key":"445_CR72","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ard.2008.089276","volume":"69","author":"JD Greenberg","year":"2010","unstructured":"Greenberg JD et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis. 2010;69:380\u20136.","journal-title":"Ann Rheum Dis"},{"key":"445_CR73","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/ard.2010.137422","volume":"70","author":"D Salmon-Ceron","year":"2011","unstructured":"Salmon-Ceron D et al. Drug specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3 year prospective French RATIO registry. Ann Rheum Dis. 2011;70:616\u201323. A large, prospective cohort study describing the incidence of OI in French patients on TNFi.","journal-title":"Ann Rheum Dis"},{"key":"445_CR74","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.2007.072967","volume":"67","author":"T Takeuchi","year":"2008","unstructured":"Takeuchi T et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"445_CR75","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3899\/jrheum.080791","volume":"36","author":"T Koike","year":"2009","unstructured":"Koike T et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol. 2009;36(5):898\u2013906.","journal-title":"J Rheumatol"},{"issue":"7","key":"445_CR76","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3899\/jrheum.101009","volume":"38","author":"Y Komano","year":"2011","unstructured":"Komano Y et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Long term Safety. J Rheumatol. 2011;38(7):1258\u201364.","journal-title":"J Rheumatol"},{"issue":"5","key":"445_CR77","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/art.37866","volume":"65","author":"T Beukelman","year":"2013","unstructured":"Beukelman T et al. Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. Arthritis Rheum. 2013;65(5):1384\u20139.","journal-title":"Arthritis Rheum"},{"key":"445_CR78","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1093\/rheumatology\/kes244","volume":"51","author":"S Mori","year":"2012","unstructured":"Mori S, Sugimoto M. Pneumocystis jirovecii infection: an emerging threat in patients with rheumatoid arthritis. Rheumatology. 2012;51:2120\u201330. A report summarizing the concern for PJP in patients on TNFi arising from the Japanese studies on OI in this patient population.","journal-title":"Rheumatology"},{"issue":"12","key":"445_CR79","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1002\/art.27735","volume":"62","author":"G Louie","year":"2010","unstructured":"Louie G, Wang Z, Ward MW. Trends in hospitalizations for Pneumocystis jiroveci pneumonia among patients with rheumatoid arthritis in the US: 1996\u20132007. Arthritis Rheum. 2010;62(12):3826\u20139.","journal-title":"Arthritis Rheum"},{"key":"445_CR80","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/annrheumdis-2012-201338","volume":"72","author":"SAA Dartel van","year":"2013","unstructured":"van Dartel SAA et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis. 2013;72:895\u2013900.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"445_CR81","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.autrev.2012.06.008","volume":"12","author":"F Atzeni","year":"2012","unstructured":"Atzeni F et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept, and infliximab in the GISEA registry. Autoimmun Rev. 2012;12(2):225\u20139.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"445_CR82","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.autrev.2008.11.002","volume":"8","author":"EG Favalli","year":"2009","unstructured":"Favalli EG et al. Serious infections during anti-TNF\u03b1 treatment in rheumatoid arthritis patients. Autoimmun Rev. 2009;8(3):266\u201373.","journal-title":"Autoimmun Rev"},{"key":"445_CR83","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1111\/j.1440-1746.2010.06407.x","volume":"25","author":"IC Lawrance","year":"2010","unstructured":"Lawrance IC et al. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience. J Gastroenterol Hepatol. 2010;25:1732\u20138.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"445_CR84","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MPG.0b013e3181c2c10d","volume":"51","author":"J Tschudy","year":"2010","unstructured":"Tschudy J, Michail S. Disseminated histoplasmosis and Pneumocystis pneumonia is a child with Crohn\u2019s disease receiving infliximab. J Pediatr Gastroenterol Nutr. 2010;51(2):221\u20132.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"445_CR85","doi-asserted-by":"crossref","first-page":"R43","DOI":"10.1186\/ar4472","volume":"16","author":"Katsuyama","year":"2014","unstructured":"Katsuyama et al. Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study. Arthritis Res Ther. 2014;16:R43.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"445_CR86","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3109\/s10165-012-0730-x","volume":"23","author":"K Takenaka","year":"2013","unstructured":"Takenaka K. A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases. Mod Rheumatol. 2013;23(4):752\u20138.","journal-title":"Mod Rheumatol"},{"issue":"10","key":"445_CR87","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/acr.21805","volume":"64","author":"JR Curtis","year":"2012","unstructured":"Curtis JR et al. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- and low-risk rheumatoid arthritis patients. Arthritis Care Res. 2012;64(10):1480\u20139.","journal-title":"Arthritis Care Res"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-014-0445-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-014-0445-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-014-0445-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T02:50:07Z","timestamp":1650077407000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-014-0445-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,3]]},"references-count":87,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["445"],"URL":"https:\/\/doi.org\/10.1007\/s11926-014-0445-4","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,3]]},"article-number":"445"}}